Stay updated on Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedUpdated the site revision tag from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedThe page shows a minor revision update from v3.4.1 to v3.4.2, with no visible changes to study content or eligibility details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision: v3.4.1 updated from v3.4.0; no user-facing study details or functionality appear to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedMinor metadata update: Revision v3.3.4 was added and the previous Revision v3.3.3 was removed; this does not affect study content or user-facing details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check93 days agoChange DetectedAdded Location sections listing sites in Arkansas, Connecticut, Florida, Georgia, Missouri, New York, Ohio, South Carolina, Tennessee, Hainaut (Belgium), and Cluj (Romania); removed the previous location blocks, and updated the revision to v3.3.3.SummaryDifference1.0%

- Check115 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; this change does not affect study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Ipilimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in NSCLC Clinical Trial page.